Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Apellis_acquired_by_Sobi
|
| gptkbp:businessModel |
Biopharmaceuticals
|
| gptkbp:CEO |
Cedric_Francois
|
| gptkbp:clinicalTrials |
Autoimmune diseases
Thousands of participants Phase 3 Age-related macular degeneration Phase 3 trials ongoing APL-2 Advancing treatment options for patients. Innovative trial designs used Phase 2 study of Pegcetacoplan Multiple_sites_in_the_US Positive_results_for_Pegcetacoplan |
| gptkbp:collaborations |
gptkb:University_of_Pennsylvania
|
| gptkbp:communityEngagement |
Active in patient advocacy groups
|
| gptkbp:communityPartnerships |
Formed with key industry players
|
| gptkbp:employees |
200+
|
| gptkbp:financials |
Various venture capital firms
|
| gptkbp:focus |
immunology
|
| gptkbp:founded |
2009
|
| gptkbp:founder |
Cedric_Francois
|
| gptkbp:globalPresence |
Operations in multiple countries
|
| gptkbp:hasPrograms |
Composed of industry experts
|
| gptkbp:headCoach |
gptkb:Dr._John_Doe
|
| gptkbp:headquarters |
gptkb:Waltham,_MA
gptkb:Waltham,_Massachusetts |
| https://www.w3.org/2000/01/rdf-schema#label |
Apellis Pharmaceuticals
|
| gptkbp:investmentFocus |
Venture capital
OrbiMed Advisors Engages with investors regularly |
| gptkbp:leads |
Pegcetacoplan
|
| gptkbp:market |
2021
$1 billion (2023) Entered market in 2021 |
| gptkbp:marketSegment |
Focused on niche markets
|
| gptkbp:partnerships |
Multiple collaborations
Sobi |
| gptkbp:patentType |
2021
|
| gptkbp:productLine |
Diverse pipeline of therapies
|
| gptkbp:products |
Innovative therapies
Pegcetacoplan Unique_mechanism_of_action |
| gptkbp:regulatoryCompliance |
Submitted applications to regulatory bodies
FDA_approved_Pegcetacoplan |
| gptkbp:research |
Secured significant funding for research
|
| gptkbp:research_areas |
Ophthalmology
Complement inhibition Focus on novel treatments |
| gptkbp:researchFocus |
Rare diseases
|
| gptkbp:researchInterest |
Collaboration with academic institutions
Published research in peer-reviewed journals |
| gptkbp:revenue |
$100 million (2022)
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
APL-9
|
| gptkbp:type |
public company
|
| gptkbp:website |
www.apellis.com
|